Presage Biosciences is pioneering the use of human efficacy data, assessing the impact of a drug or drugs in humans before clinical trials begin, to make the cancer drug development process more efficient, productive and successful.

Our proprietary technology platform, CIVO™, allows for the rapid, reliable assessment of multiple cancer therapeutics and drug candidates in an in vivo setting, providing the first side-by-side comparison of multiple drugs and drug combinations within a single living tumor.

Presage partners with biopharmaceutical companies to help them achieve greater success by applying our approach and tools to their discovery process to improve prediction of which compounds and combinations will be most impactful. We also are actively developing in-licensed drug candidates and will use CIVO™ to develop a portfolio of promising oncology therapies to advance to the clinic.

Learn more...

Recent News:

Presage Biosciences Granted Fifth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor

October 21, 2014 | Seattle, Wash.
Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human efficacy data much earlier in drug development and clinical trials, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,834,428, covering the company’s CIVO™ arrayed microinjection platform.

One Doctor Makes The Case For Human Trials

September 4, 2014 | KUOW
Marcie Sillman talks with Fred Hutchinson cancer researcher Dr. Jim Olson about the development of a new human drug-testing model.

Presage Biosciences Presents Proof-of-Concept Data for CIVO™ Preclinical Assessment Platform at AACR 2014 Annual Meeting

April 8, 2014 | SEATTLE, Wash.
Presage Biosciences, a biotechnology company focused on bringing the earliest human efficacy data possible into cancer drug development, presented preclinical data showing that microinjection of several standard-of-care cancer drugs using its CIVO™...